Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02754596 · ClinicalTrials.gov registry record · Phase 2
Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution
A Phase 2 study, sponsored by Glaukos Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 154
- Enrollment target
NCT02754596 is a Phase 2 study that has completed, run by Glaukos Corporation. The registered enrollment target is 154 participants.
The verdict
NCT02754596, a Phase 2 study, has completed, sponsored by Glaukos Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 154 participants
- Enrollment target
Study Summary
This is a randomized trial comparing two elution doses of the Travoprost Intraocular implant to timolol ophthalmic solution.
Interventions
- DRUG Timolol Maleate Ophthalmic Solution, 0.5%
- DRUG Travoprost Intraocular Implant, high elution
- DRUG Travoprost Intraocular Implant, low elution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2016-03-29 |
| Est. Completion | 2020-07-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02754596
The ClinicalTrials.gov registry entry for NCT02754596 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glaukos Corporation, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Timolol Maleate Ophthalmic Solution, 0.5% is the first listed.
NCT02754596 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02754596 about?
NCT02754596 is a clinical study titled "Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution". This is a randomized trial comparing two elution doses of the Travoprost Intraocular implant to timolol ophthalmic solution.
What is the current status of trial NCT02754596?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 154 participants. The study started on 2016-03-29. Estimated completion is 2020-07-21.
What interventions are being tested in trial NCT02754596?
The interventions under investigation include: Timolol Maleate Ophthalmic Solution, 0.5% (DRUG), Travoprost Intraocular Implant, high elution (DRUG), Travoprost Intraocular Implant, low elution (DRUG).
Who is sponsoring clinical trial NCT02754596?
This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.